The newly patented compounds function by modulating both neurotransmitters and pro-inflammatory cytokines, offering a multi-target approach to disease management. This mechanism specifically addresses the underlying pathology of complex brain disorders, including Alzheimer’s, Parkinson’s, and Huntington’s disease. The discovery of these molecules was facilitated by PharmetRx.AI, the company's proprietary platform used to identify lead compounds across its current neurological, ophthalmologic, and dermatologic pipeline.
Afecta Pharmaceuticals Secures Patent for Glial Cell Inhibition
Irvine-based Afecta Pharmaceuticals has received U.S. Patent No. 12,673,957 for a new class of small molecule neuro-immuno modulators. The technology targets the inhibition of activated glial cells, a primary driver of inflammation that causes progressive damage to both neural and retinal tissues in patients suffering from chronic degenerative conditions.
Bruce W. Kovacs, President of Afecta, noted that the patent strengthens the firm's portfolio of multi-target therapeutics. The lead compound, AFX-770, has already demonstrated safety and efficacy in human clinical data. The company is now focusing on optimizing the delivery of AFX-770 through its engineered nanomaterials platform to ensure targeted tissue-specific results.
Comments (0)
No comments yet. Be the first!